Common use of SCREENING STANDARDS Clause in Contracts

SCREENING STANDARDS. The Board and the Union, in consultation with the Medical Provider, have determined the type of screening to be used. The only substances to be tested for, and the threshold substance levels that shall be considered a positive test result are as follows: INITIAL CONFIRMATION XXXX XXXXXXXXX XXXXX XXXXX XXXXXXXXXXXX 0000 ng/ml 300 ng/ml BARBITURATES 200 ng/ml 500 ng/ml BENZODIAZEPINES 200 ng/ml 300 ng/ml CANNABINOIDS 100 ng/ml 15 ng/ml COCAINE METABOLITE 300 ng/ml 150 ng/ml METHADONE 300 ng/ml 300 ng/ml METHAQUALONE 300 ng/ml 300 ng/ml OPIATES 300 ng/ml* 300 ng/ml *25 ng/ml if immunoassay specific for free morphine PHENCYCLIDINE (PCP) 25 ng/ml 25 ng/ml PROPOXYPHENE 300 ng/ml 300 ng/ml OXYCONTIN 100 ng/ml 100 ng/ml Should NIDA add to or delete from the current panel of controlled substances or alter the initial screening or confirmation levels, this program will be modified to confirm to NIDA standards. Employees will be notified, in writing, of such changes, within 60 days prior of its implementation. All test results shall be protected as confidential medical information as appropriate under the Americans With Disabilities Act (i.e., the test results shall be provided on a right to know basis - the employee, the Employer and the substance abuse professional - and the results shall not be presented until analyzed by a Medical Review Officer).

SCREENING STANDARDS. The Board City and the UnionFOP/OLC, in consultation with the Medical Provider, have determined the type of screening to be used. The only substances to be tested for, and the threshold substance levels that shall be considered a positive test result are as follows: DRUG INITIAL SCREENING LEVEL CONFIRMATION XXXX XXXXXXXXX XXXXX XXXXX XXXXXXXXXXXX 0000 LEVEL AMPHETAMINES 1000 ng/ml 300 ng/ml BARBITURATES 200 ng/ml 500 ng/ml BENZODIAZEPINES 200 ng/ml 300 ng/ml CANNABINOIDS 100 ng/ml 15 ng/ml COCAINE METABOLITE 300 ng/ml 150 ng/ml METHADONE 300 ng/ml 300 ng/ml METHAQUALONE 300 ng/ml 300 ng/ml OPIATES 300 ng/ml* 300 ng/ml *25 ng/ml if immunoassay specific for free morphine PHENCYCLIDINE (PCP) 25 ng/ml 25 ng/ml PROPOXYPHENE 300 ng/ml 300 ng/ml OXYCONTIN 100 ng/ml 100 ng/ml Should NIDA add to or delete from the current panel of controlled substances or alter the initial screening or confirmation levels, this program will be modified to confirm to NIDA standards. Employees will be notified, in writing, of such changes, within 60 days prior of its implementation. All test results shall be protected as confidential medical information as appropriate under the Americans With Disabilities Act (i.e., the test results shall be provided on a right to know basis - the employee, the Employer employer, and the substance abuse professional - and the results shall not be presented until analyzed by a Medical Review Officer).

SCREENING STANDARDS. The Board City and the UnionFOP/OLC, in consultation with the Medical Provider, have determined the type of screening to be used. The only substances to be tested for, and the threshold substance levels that shall be considered a positive test result are as follows: INITIAL CONFIRMATION XXXX XXXXXXXXX XXXXX XXXXX XXXXXXXXXXXX 0000 ng/ml 300 ng/ml BARBITURATES 200 ng/ml 500 ng/ml BENZODIAZEPINES 200 ng/ml 300 ng/ml CANNABINOIDS 100 ng/ml 15 ng/ml COCAINE METABOLITE 300 ng/ml 150 ng/ml METHADONE 300 ng/ml 300 ng/ml METHAQUALONE 300 ng/ml 300 ng/ml OPIATES 300 ng/ml* 300 ng/ml *25 ng/ml if immunoassay specific for free morphine PHENCYCLIDINE (PCP) 25 ng/ml 25 ng/ml PROPOXYPHENE 300 ng/ml 300 ng/ml OXYCONTIN 100 ng/ml 100 ng/ml Should NIDA add to or delete from the current panel of controlled substances or alter the initial screening or confirmation levels, this program will be modified to confirm to NIDA standards. Employees will be notified, in writing, of such changes, within 60 days prior of its implementation. All test results shall be protected as confidential medical information as appropriate under the Americans With Disabilities Act (i.e., the test results shall be provided on a right to know basis - the employee, the Employer employer and the substance abuse professional - and the results shall not be presented until analyzed by a Medical Review Officer).

SCREENING STANDARDS. The Board and the Union, in consultation with the Medical Provider, have determined the type of screening to be used. The only substances to be tested for, and the threshold substance levels that shall be considered a positive test result are as follows: INITIAL CONFIRMATION XXXX XXXXXXXXX XXXXX XXXXX XXXXXXXXXXXX 0000 DRUG SCREENING LEVEL LEVEL AMPHETAMINES 1000 ng/ml 300 ng/ml BARBITURATES 200 ng/ml 500 ng/ml BENZODIAZEPINES 200 ng/ml 300 ng/ml CANNABINOIDS 100 ng/ml 15 ng/ml COCAINE METABOLITE 300 ng/ml 150 ng/ml METHADONE 300 ng/ml 300 ng/ml METHAQUALONE 300 ng/ml 300 ng/ml OPIATES 300 ng/ml* 300 ng/ml *25 ng/ml if immunoassay specific for free morphine PHENCYCLIDINE (PCP) 25 ng/ml 25 ng/ml PROPOXYPHENE 300 ng/ml 300 ng/ml OXYCONTIN 100 ng/ml 100 ng/ml Should NIDA add to or delete from the current panel of controlled substances or alter the initial screening or confirmation levels, this program will be modified to confirm to NIDA standards. Employees will be notified, in writing, of such changes, within 60 days prior of its implementation. All test results shall be protected as confidential medical information as appropriate under the Americans With Disabilities Act (i.e., the test results shall be provided on a right to know basis - the employee, the Employer and the substance abuse professional - and the results shall not be presented until analyzed by a Medical Review Officer).

SCREENING STANDARDS. The Board City and the UnionFOP/OLC, in consultation with the Medical Provider, have determined the type of screening to be used. The only substances to be tested for, and the threshold substance levels that shall be considered a positive test result are as follows: DRUG INITIAL CONFIRMATION XXXX XXXXXXXXX SCREENING XXXXX XXXXXXXXXXXX XXXXX XXXXXXXXXXXX 0000 ng/ml 300 ng/ml BARBITURATES 200 ng/ml 500 ng/ml BENZODIAZEPINES 200 ng/ml 300 ng/ml CANNABINOIDS 100 ng/ml 15 ng/ml COCAINE METABOLITE 300 ng/ml 150 ng/ml METHADONE 300 ng/ml 300 ng/ml METHAQUALONE 300 ng/ml 300 ng/ml OPIATES 300 ng/ml* 300 ng/ml *25 ng/ml if immunoassay specific for free morphine PHENCYCLIDINE (PCP) 25 ng/ml 25 ng/ml PROPOXYPHENE 300 ng/ml 300 ng/ml OXYCONTIN 100 ng/ml 100 ng/ml Should NIDA add to or delete from the current panel of controlled substances or alter the initial screening or confirmation levels, this program will be modified to confirm to NIDA standards. Employees will be notified, in writing, of such changes, within 60 days prior of its implementation. All test results shall be protected as confidential medical information as appropriate under the Americans With Disabilities Act (i.e., the test results shall be provided on a right to know basis - the employee, the Employer employer, and the substance abuse professional - and the results shall not be presented until analyzed by a Medical Review Officer).